Corlisome^®

Corlisome® is a conditioned media derived from human umbilical cord lining mesenchymal stem cells. It contains a rich mixture of growth factors, cytokines and exosomal proteins with powerful anti-inflammatory and therapeutic potential.

Corlisome® is in development for the treatment of hair loss, initially androgenic alopecia. Corlisome® is planned as an in-clinic treatment that will be administered by a healthcare professional.

Dermal papilla cells are specialised mesenchymal cells that exist in the dermal papilla, which is located at the bottom of hair follicles. These cells play crucial roles in hair growth, formation and cycling, predominantly by secreting growth factors and molecules responsible for constructing the extracellular matrix. Over time, and due to factors such as hormones, medications or environmental conditions the number of dermal papilla cells can reduce, resulting in miniaturisation of hair follicles, which manifests as a visual appearance of hair loss.

The growth factors within Corlisome® have multiples potential actions within the hair growth cycle to delay the process of miniaturisation associated with androgenic alopecia.

Prolonging the growth phase (anagen) of hair Reducing the hair loss (exogen) Provision of depleted growth factors and cytokines involved in the function of the dermal papilla Counteracting chronic inflammation linked to the process of miniaturisation Corlisome builds on extensive data generated by Cell Research Consumer Health who have a cosmetic formulation of enriched supernatant derived from a mammalian source for hair loss with promising results. It is anticipated that a human-sourced, biopharmaceutical grade of product with potential for injection into the scalp will yield highly promising results and offer a new therapeutic option for this common condition.